

This use model depicts the various steps involved in providing personalized treatment for the prescription of drug therapies to determine their efficacy and safety on Pilot for TPMT(Thiopurine) and CYP2C19(Plavix) candidate patients. Drugs in this category are known to elicit considerable variability in individual response based on the patient's genetic make-up.

Created by Kristen Janes, Dr. Brian Pech from Kaiser Permanente and Priyadarshini.Ravindran from Allscripts Version 1.0 10/23/2014



Internal Lab. Genetics Provider, External Lab consistent across use models



LIS System & or GLIS Point of Origin 6. Genomic Source (Blood, Saliva, Urine, Tissue) 7. Date/Time Collected 8. Date/Time of Sign Out 9. Report Status 10. Performing Lab 11. Accession ID 12. Test Coverage 13. Description of the Analytical Method for Lab developed tests 14. CAP Certification 15. Region of Interest specified through genomi-, 15, 17, 19 coordinates for point May also be mutations and start and sto nultiple fields coordinates for genomic sequencing. 16. Includes structural variant assessment (T/F) 17. List of Genes Assessed 18. Gene Result [Automate Physician, variance reported 19. ATM or variants detecte or specified RSID if available; specify reference sequence for gene {and genomic location of variant or reference sequence for protein and AA substitution, e.g. ATM:pv2424g} 20. Zygosity 21. Overall result 22. Conditions of specimen that may limit adequacy of testina 23. Report can be text, PDF,

Definition comes rom standards group 24. Confidentiality HL7 (is classification system)

Weblink